EP3564251A1 - Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant - Google Patents

Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant Download PDF

Info

Publication number
EP3564251A1
EP3564251A1 EP17888291.6A EP17888291A EP3564251A1 EP 3564251 A1 EP3564251 A1 EP 3564251A1 EP 17888291 A EP17888291 A EP 17888291A EP 3564251 A1 EP3564251 A1 EP 3564251A1
Authority
EP
European Patent Office
Prior art keywords
seq
rebaudioside
nucleotide sequence
steviol glycoside
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17888291.6A
Other languages
German (de)
English (en)
Other versions
EP3564251A4 (fr
Inventor
Kazunari Iwaki
Katsuro Miyagawa
Eiichiro Ono
Tadayoshi HIRAI
Misa Ochiai
Koji Nagao
Soichiro Urai
Takehiro Watanabe
Kohki Fujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of EP3564251A1 publication Critical patent/EP3564251A1/fr
Publication of EP3564251A4 publication Critical patent/EP3564251A4/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/205—Heterocyclic compounds
    • A23L27/2052—Heterocyclic compounds having oxygen or sulfur as the only hetero atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Definitions

  • the present invention relates to a novel steviol glycoside, a method for producing the same, and a sweetener composition containing the same. Furthermore, the present invention also relates to a food or beverage, a plant, an extract thereof and a flavor controlling agent containing the novel steviol glycoside.
  • Steviol is one type of diterpenoid, where steviol glycoside provides sweetness that is nearly 300 times the sweetness of sugar and is therefore utilized as a calorieless sweetener in the food industry.
  • the demand for calorieless sweeteners is growing day by day as obesity has become a serious social problem worldwide and also for the sake of health promotion and reduction in the medical expenditure.
  • aspartame and acesulfame potassium which are artificially synthesized amino acid derivatives, are utilized as artificial sweeteners, but natural calorieless sweeteners like the steviol glycosides are expected to be safer and more likely to gain public acceptance.
  • the major steviol glycosides from stevia are ultimately glycosylated to a glycoside named rebaudioside A (Reb.A) that has four sugar moieties ( Figure 1 ).
  • Stevioside namely, a tri-glycosylated steviol glycoside and a precursor of Reb.A, is the most abundant glycoside. These two glycosides are the main substances responsible for the sweetness of stevia. Stevioside accounts for the largest content in stevia leaves and is known to provide sweetness that is about 250-300 times the sweetness of sugar.
  • Reb.A is a tetra-glycosylated steviol glycoside that has strong sweetness (350-450 times sugar) with good taste quality. They have been drawing attention as calorieless sweeteners.
  • glycosides that are considered to be reaction intermediates and analogs having different types of sugar moieties.
  • Reb.A all of the four glycoside sugar moieties of Reb.A are glucose
  • rebaudioside C (Reb.C) is known to have rhamnose instead of glucose attached to C-2 of glucose at C-13
  • rebaudioside F (Reb.F) is known to have xylose attached at the same position.
  • Patent Document 1 Japanese Patent No. 3436317
  • some stevia cultivars resulting from breeding may contain a minute amount of steviol glycoside whose structure is not yet identified, where the presence of such steviol glycoside present in minute quantity may potentially be contributing to the flavor characteristic of the stevia extract.
  • steviol glycosides obtained by further attaching glucose to Reb.A and on cultivars containing the same, not much research has been made at this point on cultivars containing an abundant amount of a steviol glycoside having rhamnose like Reb.C and on such a steviol glycoside.
  • the objective of the present invention is to determine the structure of a novel steviol glycoside present in minute quantity that affects the taste quality, and to identify the characteristics of its taste quality.
  • further objectives of the present invention are to provide a novel steviol glycoside, a method for producing the same, and a sweetener composition containing the same.
  • the present inventors have gone through extensive investigation to solve the above-described problem, and as a result of which succeeded in determining the structure of the novel steviol glycoside present in minute quantity that affects the taste quality.
  • the present invention was made based on the above-described finding.
  • the present invention can provide a novel steviol glycoside present in minute quantity that affects the taste quality. Furthermore, the present invention can also provide a method for producing the novel steviol glycoside, and a sweetener composition, a food or beverage, a plant, an extract thereof and a flavor controlling agent containing the novel steviol glycoside.
  • the novel steviol glycoside of the present invention (hereinafter, also referred to as the "glycoside of the present invention") is a compound represented by Formula (1): or a derivative, a salt or a hydrate thereof.
  • the glycoside of the present invention has a sugar chain containing three glucose moieties at C-19 of steviol and a sugar chain containing two glucose moieties and one rhamnose moiety at C-13.
  • the glycoside of the present invention may be not only the compound represented by Formula (1) but may also be a derivative, a salt or a hydrate thereof.
  • derivative refers to a compound resulting from a structural change of a minor moiety of the compound, for example, a compound in which some of the hydroxyl groups are substituted with other substituents. Therefore, derivatives of the compound represented by Formula (1) include compounds in which some of the hydroxyl groups contained in the compound have been substituted with a substituent selected from hydrogen, a halogen, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an amino group, a cyano group or the like.
  • a “salt of the compound represented by Formula (1)” refers to a physiologically acceptable salt, for example, a sodium salt, of the compound represented by Formula (1).
  • a “hydrate of the compound represented by Formula (1)” as used herein refers to a compound resulting from addition of a water molecule to the compound represented by Formula (1).
  • the glycoside of the present invention is not particularly limited, it may be a plant-derived product, a chemically synthesized product or a biosynthetic product. For example, it may be isolated and purified from a plant with abundant Reb.C, or it may be obtained by chemical synthesis or biosynthesis. Details of a method for producing a glycoside of the present invention will be described later herein.
  • the glycoside of the present invention is sweeter than sugar (sucrose), has taste quality of good lingering sweet aftertaste, and can affect the taste quality of foods/beverages in a small amount.
  • sugar saccharide
  • the glycoside of the present invention can be used as a novel sweetener.
  • the novel steviol glycoside of the present invention is a compound represented by Formula (A): or a derivative, a salt or a hydrate thereof.
  • a sweetener composition containing the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof (hereinafter, also referred to as the "sweetener composition of the present invention") is provided.
  • the sweetener composition of the present invention is not particularly limited as long as it contains the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof, and it may be a composition containing an extract containing the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof.
  • the amount of the glycoside of the present invention contained in the sweetener composition of the present invention is not particularly limited.
  • the sweetener composition of the present invention is preferably a composition containing the glycoside of the present invention in a larger amount than the amount in a wild-type stevia or stevia extract by at least 0.01%.
  • the glycoside of the present invention was detected for the first time in a cultivar containing abundant Reb.C, and it is not contained in a wild-type stevia or an extract thereof at all or, if any, contained in an amount at the detection limit or below.
  • the sweetener composition of the present invention may further contain other steviol glycosides.
  • the sweetener composition of the present invention may contain, in addition to the glycoside of the present invention, one or more types of steviol glycosides selected from the group consisting of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside Q, rebaudioside R, dulcoside A, rubusoside, steviol, steviol monoside, steviol bioside and stevioside.
  • the composition ratio of the glycoside of the present invention and other steviol glycoside is preferably 0.01:9.99-6:4 in a mass ratio.
  • the sweetener composition of the present invention may further contain a general sweetener.
  • a general sweetener include natural sweeteners such as fructose, sugar, fructose-glucose syrup, glucose, maltose, sucrose, high-fructose syrup, sugar alcohol, oligosaccharide, honey, pressed sugarcane juice (brown sugar syrup), starch syrup, Lo Han Kuo ( Siraitia grosvenorii ) powder, Lo Han Kuo extract, licorice powder, licorice extract, Thaumatococcus daniellii seed powder and Thaumatococcus daniellii seed extract, and artificial sweeteners such as acesulfame potassium, sucralose, neotame, aspartame and saccharin.
  • natural sweeteners are preferably used from the aspect of imparting clean taste, easy drinkability, natural flavor and moderately rich taste, where fructose, glucose, maltose, sucrose and sugar are particularly preferably used. Either a single type or a plurality of types of these sweetness ingredients may be used.
  • a food or beverage containing the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof (hereinafter, also referred to as the "food or beverage of the present invention") is provided.
  • the food or beverage of the present invention is not particularly limited as long as it contains the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof, and it may be a food or beverage containing an extract containing the compound represented by Formula (1), or a derivative, a salt or a hydrate thereof.
  • a food or beverage refers to foods and beverages. Therefore, in some embodiments, the present invention provides a novel food or beverage, and a method for producing said food or beverage.
  • the amount of the glycoside of the present invention contained in the food or beverage of the present invention differs depending on the specific food or beverage, it is preferably around 0.0004%-0.8% and particularly preferably 0.04%-0.4%. As long as the content lies within this range, the lingering aftertaste can advantageously be suppressed.
  • the food or beverage of the present invention may further contain other steviol glycosides.
  • the sweetener composition of the present invention may contain, in addition to the glycoside of the present invention, one or more types of steviol glycosides selected from the group consisting of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside Q, rebaudioside R, dulcoside A, rubusoside, steviol, steviol monoside, steviol bioside and stevioside.
  • the composition ratio of the glycoside of the present invention and other steviol glycoside is preferably 0.01:9.99-6:4 in a mass ratio.
  • the food or beverage of the present invention may further contain a general sweetener.
  • a general sweetener include natural sweeteners such as fructose, sugar, fructose-glucose syrup, glucose, maltose, sucrose, high-fructose syrup, sugar alcohol, oligosaccharide, honey, pressed sugarcane juice (brown sugar syrup), starch syrup, Lo Han Kuo ( Siraitia grosvenorii) powder, Lo Han Kuo extract, licorice powder, licorice extract, Thaumatococcus daniellii seed powder and Thaumatococcus daniellii seed extract, and artificial sweeteners such as acesulfame potassium, sucralose, neotame, aspartame and saccharin.
  • natural sweeteners such as fructose, sugar, fructose-glucose syrup, glucose, maltose, sucrose, high-fructose syrup, sugar alcohol, oligosaccharide
  • natural sweeteners are preferably used from the aspect of imparting clean taste, easy drinkability, natural flavor and moderately rich taste, where fructose, glucose, maltose, sucrose and sugar are particularly preferably used. Either a single type or a plurality of types of these sweetness ingredients may be used.
  • Examples of the food of the present invention include, but not particularly limited to, a confection, a bread, cereal flour, noodles, rice, a processed agricultural/forestry food, a processed livestock product, a processed fishery product, a milk/dairy product, an oil-and-fat/processed oil-and-fat product, seasoning or other food material.
  • beverage of the present invention examples include, but not particularly limited to, a carbonated beverage, a non-carbonated beverage, an alcoholic beverage, a non-alcoholic beverage, a coffee beverage, a tea beverage, a cocoa beverage, a nutritious beverage and a functional beverage.
  • the beverage of the present invention may be heat sterilized and packaged to be prepared as a packaged beverage.
  • package include, but not particularly limited to, a PET bottle, an aluminum can, a steel can, a paper package, a chilled cup, and a bottle.
  • heat sterilization may be performed by employing a common technique such as UHT sterilization, retort sterilization or the like.
  • the temperature during the heat sterilization process is not particularly limited, it is, for example, 65-130°C, and preferably 85-120°C, for 10-40 minutes. Sterilization, however, can be carried out at an appropriate temperature for a several seconds, for example, 5-30 seconds, without problem as long as the same sterilizing value as that under the above-described conditions can be earned.
  • a plant containing the novel steviol glycoside and an extract thereof are provided.
  • a food or beverage, preferably a beverage, containing the plant of the present invention or an extract of the plant is provided. While the amount of the glycoside of the present invention contained in the plant of the present invention is not particularly limited, it is preferably 0.001%-1.000% and more preferably 0.01%-0.80%.
  • the plant of the present invention is a plant that contains the glycoside of the present invention in a larger amount than a wild-type stevia species by 0.01% or more.
  • the steviol glycoside of the present invention is not contained in a wild-type stevia at all or, if any, contained in an amount of the detection limit or less.
  • the phrase "contains the glycoside of the present invention in a larger amount than a wild-type stevia species by 0.01% or more” means that, with respect to an amount (concentration) of the glycoside of the present invention contained per unit quantity (e.g. 10 ml) of a liquid extract from fresh leaves (undried leaves) of a wild-type stevia plant, an amount (concentration) of the glycoside of the present invention contained in an equal unit quantity of a liquid extract from fresh leaves (undried leaves) of the plant of the present invention (the same amount as that of the liquid extract from the leaves of the wild-type stevia plant) is higher by 0.01% or more.
  • the plant of the present invention may contain the glycoside of the present invention in a larger amount than a wild-type stevia species by 0.02% or more, 0.03% or more, 0.04% or more, 0.05% or more, 0.07% or more, 0.09% or more, 0.10% or more, 0.15% or more, 0.20% or more, 0.40% or more, 0.60% or more, 0.80% or more, 1.0% or more, 1.50% or more, 2.00% or more, 4.00% or more, 6.00% or more, 8.00% or more, or 10.00% or more.
  • the phrase "the proportion of the glycoside of the present invention among the total steviol glycosides is 0.01% or more" means that the glycoside of the present invention exists at a percentage of 0.01% or more with respect to the total content of the steviol glycosides existing in the liquid extract from the fresh leaves (undried leaves) of the stevia plant of the present invention.
  • the total steviol glycosides neither contain unknown steviol glycosides nor any steviol glycoside existing in an amount less than the detection limit.
  • the total steviol glycosides consist of rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rebaudioside I, rebaudioside J, rebaudioside K, rebaudioside N, rebaudioside M, rebaudioside O, rebaudioside Q, rebaudioside R, dulcoside A, rubusoside, steviol, steviol monoside, steviol bioside and stevioside.
  • the glycoside of the present invention may exist in an amount of 0.01 wt% or more, 0.02 wt% or more, 0.03 wt% or more, 0.04 wt% or more, 0.05 wt% or more, 0.07 wt% or more, 0.10 wt% or more, 0.15 wt% or more, 0.20 wt% or more, 0.30 wt% or more, 0.50 wt% or more, 0.60 wt% or more, 0.80 wt% or more, 1.00 wt% or more, 2.00 wt% or more, 4.00 wt% or more, 6.00 wt% or more, 8.00 wt% or more, or 10.00 wt% or more with respect to the weight of said dried leaves.
  • dried leaves of the plant of the present invention refer to those obtained by drying fresh leaves of the plant of the present invention to reduce their water content to 10 wt% or less, 7 wt% or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, or 1 wt% or less.
  • the water content of the dried leaves of the plant of the present invention is 3-4 wt%.
  • Examples of the plant of the present invention include plants with abundant Reb.C.
  • the steviol glycoside of the present invention is not contained in a wild-type stevia or an extract thereof at all or, if any, contained in an amount of the detection limit or less.
  • the present inventors found out that the steviol glycoside of the present invention is contained in a larger amount in a plant having abundant Reb.C. Therefore, the novel steviol glycoside and the extract thereof also comprise such a plant with abundant Reb.C and an extract thereof.
  • Examples of such a plant with abundant Reb.C include, but are not particularly limited to, high-rebaudioside C-containing non-recombinant stevia plants which contain rebaudioside C in a larger amount than a wild-type stevia species by 20% or more, and whose proportion of rebaudioside C among the total steviol glycosides is 40% or more (hereinafter, also referred to as a "high-Reb.C plant").
  • Examples of such a high-Reb.C plant include high-rebaudioside C-containing non-recombinant stevia plants which contain rebaudioside C in a larger amount than a wild-type stevia species by 20% or more, and whose proportion of rebaudioside C among the total steviol glycosides is 40% or more.
  • a high-Reb.C plant is a cultivar derived from a plant of a wild-type stevia, in which genetic mutation has occurred to increase rebaudioside C.
  • genetic mutation include, but not particularly limited to, genetic mutation induced under naturally occurring conditions, genetic mutation induced by a non-recombinational technique and genetic mutation induced by genetic recombination.
  • a high-Reb.C plant can be screened, for example, by detecting gene polymorphism in the tissue of the plant.
  • screening means to identify a high-Reb.C plant among other plants and to select the high-Reb.C plant.
  • the high-Reb.C plant may also be screened according to a screening method that includes a step of identifying a polymorphism of A in the wild type being altered to T at the 60th nucleotide of the nucleotide sequence represented by SEQ ID NO:11 in the genome of a test plant.
  • a plant of the present invention not only comprises whole plants but may also include plant organs (for example, leaf, petal, stem, root, seed, etc.), plant tissues (for example, epidermis, phloem, parenchyma, xylem, vascular bundles, palisade tissue, spongy tissue, etc.), various forms of plant cells (for example, suspension cultured cells), a protoplast, a leaf piece, callus and the like.
  • plant organs for example, leaf, petal, stem, root, seed, etc.
  • plant tissues for example, epidermis, phloem, parenchyma, xylem, vascular bundles, palisade tissue, spongy tissue, etc.
  • various forms of plant cells for example, suspension cultured cells
  • a protoplast for example, a leaf piece, callus and the like.
  • a plant of the present invention may also comprise a tissue culture or a plant cell culture. This is because such a tissue culture or plant cell culture may be cultured to regenerate a plant.
  • tissue culture or the plant cell culture of the plant of the present invention include, but not limited to, an embryo, meristematic cells, pollen, a leaf, a root, a root apex, a petal, a protoplast, a leaf piece and callus.
  • An extract of a plant of the present invention can be obtained by reacting a fresh leaf or a dried leaf of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether or acetone).
  • an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether or acetone.
  • the extract of the plant of the present invention contains the glycoside of the present invention in a larger amount than a wild-type stevia by 0.01% or more, where the proportion of the glycoside of the present invention among the total steviol glycosides is 0.01% or more.
  • the phrase "contains the glycoside of the present invention in a larger amount than a wild-type stevia by 0.01% or more” means the same as described above.
  • the phrase the "proportion of the glycoside of the present invention among the total steviol glycosides is 0.01% or more” also means the same as described above.
  • novel steviol glycoside of the present invention is contained in a stevia extract in a minute quantity, it is considered to have an influence on the flavor of the stevia extract. While not wishing to be bound by any theory, addition of a small amount of the steviol glycoside of the present invention is presumed to be capable of controlling the flavor of a food or beverage. Therefore, in one aspect of the present invention, a flavor controlling agent containing the above-described compound represented by Formula (1) or a derivative, a salt or a hydrate thereof is provided.
  • a "flavor controlling agent” refers to a substance that can be added to a food or beverage to control the flavor of the food or beverage.
  • the flavor controlling agent of the present invention can be added to a food or beverage so as to control the flavor of the food or beverage itself without the consumers recognizing the taste of the flavor controlling agent itself.
  • the steviol glycoside of the present invention has good lingering sweet aftertaste as compared to conventional steviol glycosides, it can be used as a flavor controlling agent for controlling the lingering sweet aftertaste of the food or beverage.
  • the flavor controlling (enhancing) agent of the present invention preferably contains, in addition to the above-described compound represented by Formula (1) or a derivative, a salt or a hydrate thereof, one or more types of other sweeteners.
  • sweetener include: one or more types of steviol glycosides selected from the group consisting of rebaudioside A, rebaudioside D, rebaudioside B, rebaudioside M, rebaudioside N, rebaudioside O, rebaudioside E, rebaudioside K and rebaudioside J; natural sweeteners such as fructose, sugar, fructose-glucose syrup, glucose, maltose, sucrose, high-fructose syrup, sugar alcohol, oligosaccharide, honey, pressed sugarcane juice (brown sugar syrup), starch syrup, Lo Han Kuo ( Siraitia grosvenorii ) powder, Lo Han Kuo extract, licorice powder, licorice extract, Thaumatococcus
  • the flavor controlling agent of the present invention is a flavor controlling agent that improves lingering aftertaste and that contains the compound represented by Formula (1) or a derivative, a salt or a hydrate thereof.
  • Brix of commercially available foods or beverages for example, refreshing beverages
  • reduction in the amount of sugar in foods or beverages has been considered due to the recent growth of health consciousness and the introduction of sugar tax.
  • use of a non-sugar sweetener for example, a non-calorie sweetener
  • Brix will be 5.
  • a non-sugar sweetener to make up for the sweetness level corresponding to Brix of 5.
  • Many of the non-sugar sweeteners have unique flavors that differ from sugar, where one of such characteristic flavors is bad lingering sweet aftertaste.
  • a flavor controlling agent containing the steviol glycoside of the present invention can be used as a flavor controlling agent for improving the lingering aftertaste.
  • “Brix” is a scale of a sweetness level of a food or beverage, that is, a value of the concentration of the soluble solid content expressed in a weight percent concentration in a sucrose solution at 20°C.
  • sucrose (g) in 100 g of an aqueous sucrose solution For example, Brix of 5 represents a sweetness level corresponding to the sweetness level of 5 g of sucrose in 100 g of an aqueous sucrose solution.
  • the flavor controlling agent of the present invention is preferably added to the non-sugar sweetener contained in a food or beverage in an amount of 1 mass%-15 mass% based on the mass of the sweetener.
  • the flavor controlling agent of the present invention is added more preferably in an amount of 1.5 mass%-12 mass%, and still more preferably in an amount of 3.5 mass%-11 mass% based on the mass of the sweetener.
  • the content of the non-sugar sweetener in the food or beverage added with the flavor controlling agent of the present invention is preferably 5-13, more preferably 5-12 and still more preferably 5-7 in terms of Brix.
  • the phrase "the content of the non-sugar sweetener is 5 in terms of Brix” refers to a content that gives the sweetness of the aqueous solution containing the non-sugar sweetener to be equivalent to Brix of 5.
  • the amount that gives "the content of the non-sugar sweetener to be 5 in terms of Brix" is 0.025 g in 100 g of an aqueous solution containing the non-sugar sweetener.
  • a flavor controlling agent of the present invention is added to the non-sugar sweetener contained in the food or beverage in an amount of 1 mass%-15 mass% based on the mass of the sweetener, wherein the content of the non-sugar sweetener is 5.5-12 in terms of Brix.
  • the flavor controlling agent of the present invention is added to the non-sugar sweetener contained in the food or beverage in an amount of 1.5 mass%-12 mass% based on the mass of the sweetener, wherein the content of the non-sugar sweetener is 5-13 in terms of Brix.
  • sweetener contained in the food or beverage examples include, but not limited to: one or more types of steviol glycoside selected from the group consisting of rebaudioside A, rebaudioside D, rebaudioside B, rebaudioside M, rebaudioside N, rebaudioside O, rebaudioside E, rebaudioside K and rebaudioside J; natural sweeteners such as fructose, fructose-glucose syrup, glucose, maltose, high-fructose syrup, sugar alcohol, oligosaccharide, honey, pressed sugarcane juice (brown sugar syrup), starch syrup, Lo Han Kuo ( Siraitia grosvenorii) powder, Lo Han Kuo extract, licorice powder, licorice extract, Thaumatococcus daniellii seed powder and Thaumatococcus daniellii seed extract; and artificial sweeteners such as acesulfame potassium, sucralose, neotam
  • a flavor controlling agent of the present invention is a flavor controlling agent containing the above-described compound represented by Formula (1) or a derivative, a salt or a hydrate thereof for enhancing sweetness.
  • a flavor controlling agent for enhancing sweetness refers to a flavor controlling agent that can be added to a food or beverage containing a sweetener so that it can impart stronger sweetness to the food or beverage than a simple sum of the sweetness of the flavor controlling agent thereto.
  • the flavor controlling agent when a flavor controlling agent of an amount equivalent to Brix of 0.1 is added to a food or beverage with sweetness equivalent to Brix of 9, the flavor controlling agent should be capable of imparting a sweetness level exceeding Brix of 9.1 (for example, Brix of 9.2) to the food or beverage.
  • Brix of 9.1 for example, Brix of 9.2
  • the flavor controlling agent for enhancing sweetness of the present invention is preferably added in an amount of 0.05 mass%-2.0 mass%, more preferably added in an amount of 0.1 mass%-1.5 mass%, and still more preferably added in an amount of 0.2 mass%-1.2 mass% based on the mass of the sweetener targeted for sweetness enhancement.
  • sweetener targeted for sweetness enhancement examples include, but not particularly limited to: one or more types of steviol glycoside selected from the group consisting of rebaudioside A, rebaudioside D, rebaudioside B, rebaudioside M, rebaudioside N, rebaudioside O, rebaudioside E, rebaudioside K and rebaudioside J; natural sweeteners such as fructose, sugar, fructose-glucose syrup, glucose, maltose, sucrose, high-fructose syrup, sugar alcohol, oligosaccharide, honey, pressed sugarcane juice (brown sugar syrup), starch syrup, Lo Han Kuo ( Siraitia grosvenorii ) powder, Lo Han Kuo extract, licorice powder, licorice extract, Thaumatococcus daniellii seed powder and Thaumatococcus daniellii seed extract; and artificial sweeteners such as acesulfame potassium, sucralose,
  • the steviol glycoside of the present invention can be produced by (A) isolation/purification from a plant, (B) a chemical synthesis, or (C) a biosynthesis.
  • A isolation/purification from a plant
  • B chemical synthesis
  • C a biosynthesis
  • the novel steviol glycoside can be isolated/purified from said plant.
  • a fresh or dried leaf of the plant of the present invention is allowed to react with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether or acetone) to extract the novel steviol glycoside in a liquid extract state.
  • an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether or acetone
  • the resulting liquid extract may be subjected to a known method such as a gradient of ethyl acetate or other organic solvent: water, high performance liquid chromatography (HPLC), or ultra (high) performance liquid chromatography (UPLC) to isolate/purify the novel steviol glycoside.
  • HPLC high performance liquid chromatography
  • UPLC ultra (high) performance liquid chromatography
  • the content of the novel steviol glycoside in the plant can be determined by the method described in WO2016/090460 or the method described in the example below. Specifically, the content can be measured by sampling fresh leaves from the plant of the present invention and subjecting the leaves to LC-MS/MS.
  • Steviol glycosides have structures in which different sugar moieties (glucose, rhamnose, xylose, etc.) are attached to the aglycone, i.e. steviol, via various linkage forms (linkage positions and conformations). Therefore, a steviol glycoside of interest can be obtained via various pathways depending on the selected starting material. Those skilled in the art to which the present invention pertains, however, wound understand that the time and the yield for obtaining the compound of interest greatly vary depending on the synthetic pathways.
  • a chemical synthesis of the steviol glycoside proceeds by separating the steviol glycoside into a "steviol glycoside” and a "sugar hemiacetal form" as shown in Scheme 1.
  • the steviol glycoside can be prepared by deriving from an existing natural substance (rebaudioside, dulcoside, stevioside, steviol bioside, rubusoside, etc.). Meanwhile, the sugar hemiacetal form can be prepared either from an existing natural substance or by a chemical synthesis. The present inventors found that the steviol glycoside of interest can be obtained with good yield and extremely high ⁇ -selectivity by condensing the steviol glycoside and the sugar hemiacetal form through the Mitsunobu reaction.
  • a method for producing the compound represented by Formula (1) comprises the steps of:
  • the method for producing the compound represented by Formula (1) where the method further comprises a step of allowing reaction between the compound represented by Formula (3) above and the compound represented by Formula (4) above in the presence of a phosphine reagent and an azo compound to obtain a compound represented by Formula (5) below (wherein, PGs each independently represents a protecting group).
  • examples of the protecting group include an acyl protecting group, a trisubstituted silyl group, an acetal protecting group and an ether protecting group.
  • Preferable examples include a trisubstituted silyl group (a trimethylsilyl group, a triethylsilyl group, a t-butyldimethylsilyl group, etc.) and an acyl protecting group (an acetyl group, a benzoyl group, etc.).
  • a steviol glycoside can be obtained, for example, by following Scheme 2 below using naturally occurring rebaudioside C (dulcoside B) as a raw material.
  • rebaudioside C is dissolved in a solvent such as methanol and water, added with a strong base such as sodium hydroxide, and refluxed at 60°C-120°C for 2 hours or longer so that the glucose molecule is removed from C-19 of rebaudioside C to give Compound 2 above.
  • the solvent may be evaporated after neutralizing the reaction solution with a cation exchange resin or the like.
  • Compound 2 is further dissolved in a solvent such as pyridine, and added with acetic anhydride or the like to protect the hydroxyl groups contained in Compound 2, thereby obtaining Compound 3.
  • a solvent such as pyridine
  • the trisaccharide hemiacetal can be obtained, for example, by following Scheme 3 below using a commercially available glucopyranoside derivative as a raw material.
  • Compound 7 is dissolved in a solvent such as ethanol, added with P-toluenesulfonic acid at room temperature, agitated at 60°C-80°C for 2 hours or longer to complete the reaction, then neutralized with triethylamine, and concentrated under a reduced pressure.
  • the resulting syrup is dissolved in a solvent such as pyridine, and added with acetic anhydride or the like to give Compound 8 with protected hydroxyl groups.
  • Compound 8 is dissolved in acetonitrile and water, added with an oxidant such as cerium ammonium nitrate, and agitated for 5 minutes to 2 hours, thereby obtaining Compound 9.
  • the compound represented by Formula (1) can be synthesized, for example, by following Scheme 4 below using Compounds 3 and 9 obtained in Steps 1 and 2 above.
  • the trisaccharide hemiacetal form and the steviol glycoside obtained in Steps 1 and 2 are allowed to undergo the Mitsunobu reaction so that only Compound 10 in the ⁇ -form can selectively be obtained with very high yield (45% or more).
  • these compounds are dissolved in 1,4-dioxane, added with a phosphine reagent such as tributylphosphine or triphenylphosphine and an azo compound such as 1,1'-azobis (N,N'-dimethylformamide) (TMAD) at room temperature, and agitated at 50°C-80°C for 2 hours or longer to give only Compound 10 in the ⁇ -form.
  • TMAD 1,1'-azobis (N,N'-dimethylformamide)
  • the steviol glycoside of the present invention can also be generated by transferring a polynucleotide coding for a predetermined protein into a host cell derived from a bacterium, a plant, an insect, a non-human mammal or the like, and using steviol, a steviol glycoside, UDP-glucose and/or UDP-rhamnose as a substrate.
  • Steviol, a steviol glycoside, UDP-glucose or UDP-rhamnose as the substrate may be either provided or biosynthesized in the cell.
  • examples of the predetermined protein include stevia-derived UGT85C2 (the amino acid sequence represented by SEQ ID NO:2), UGT74G1 (the amino acid sequence represented by SEQ ID NO:4), UGT91D2 (the amino acid sequence represented by SEQ ID NO:6), UGT76G1 (the amino acid sequence represented by SEQ ID NO:8) and Arabidopsis thaliana-derived UDP-rhamnose synthase AtRHM2 (the amino acid sequence represented by SEQ ID NO: 10), it is not limited thereto as long as it has an equivalent activity.
  • the above-described protein is an enzyme derived from Arabidopsis thaliana or stevia, which is expected to be highly active in an environment outside plant cells such as Arabidopsis thaliana and stevia (for example, in an extracellular environment, or inside a host cell other than stevia).
  • the polynucleotide coding for the above-described protein (for example, UGT85C2 gene is represented by SEQ ID NO:1, UGT74G1 gene is represented by SEQ ID NO:3, UGT91D2 gene is represented by SEQ ID NO:5, UGT76G1 gene is represented by SEQ ID NO:7 and AtRHM2 gene is represented by SEQ ID NO:9) is transferred into a host cell derived from a bacterium, a fungus, a plant, an insect or a non-human mammal so as to allow expression of the protein of the present invention, to which steviol, a steviol glycoside, UDP-glucose or UDP-rhamnose as the substrate is provided to generate the compound of the present invention.
  • the above-described protein is expressed in the host cell, to which an appropriate substrate is provided to generate the compound of the present invention.
  • a method for producing the novel steviol glycoside of the present invention is provided, where the method is characterized by use of a non-human transformant that has been introduced with at least one of polynucleotides (a) to (g) below.
  • polynucleotides independently having 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, 99% or higher, 99.1% or higher, 99.2% or higher, 99.3% or higher, 99.4% or higher, 99.5% or higher, 99.6% or higher, 99.7% or higher, 99.8% or higher, or 99.9% or higher sequence identity with the nucleotide sequences of the sequence numbers mentioned in (a) to (g) above can be used.
  • proteins that independently have an amino acid sequence having 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, 99% or higher, 99.1% or higher, 99.2% or higher, 99.3% or higher, 99.4% or higher, 99.5% or higher, 99.6% or higher, 99.7% or higher, 99.8% or higher, or 99.9% or higher sequence identity with the amino acid sequences of the sequence number mentioned in (a) to (g) above and that has the predetermined activity described in (a) to (g) above can be used.
  • a polynucleotide coding for the above-described protein is introduced into a host while being inserted into an appropriate expression vector.
  • the polynucleotides may individually be inserted into separate vectors.
  • An appropriate expression vector is generally made to contain:
  • Examples of a method for preparing an expression vector include, but not particularly limited to, a method that uses a plasmid, a phage, a cosmid or the like, and DNA molecules having necessary components.
  • the type of the vector is not particularly limited, and any vector that allows expression in the host cell can suitably be selected.
  • a promoter sequence is suitably selected according to the type of the host cell to ensure expression of the polynucleotide of the present invention, and a vector obtained by integrating this promoter sequence and the polynucleotide of the present invention into a plasmid or the like is used as an expression vector.
  • the expression vector of the present invention includes expression controlling regions (for example, a promoter, a terminator and/or an origin of replication and the like) depending on the type of the host into which it is introduced.
  • a promoter used in a bacterial expression vector may be a common promoter (for example, a trc promoter, a tac promoter, a lac promoter, etc.)
  • a promoter used for a yeast may be, for example, a glyceraldehyde-3-phosphate dehydrogenase promoter, PH05 promoter, a GAL1/10 promoter or the like
  • a promoter for filamentous fungi may be, for example, amylase, trpC or the like.
  • examples of a promoter for expressing the gene of interest in a plant cell include a cauliflower mosaic virus 35S RNA promoter, a rd29A gene promoter, a rbcS promoter, and a mac-1 promoter in which the enhancer sequence of the cauliflower mosaic virus 35S RNA promoter is provided at the 5' end of a promoter sequence of Agrobacterium-derived mannopine synthase.
  • a promoter for an animal cell host may be a viral promoter (for example, a SV40 early promoter, a SV40 late promoter, etc.).
  • a promoter that is inducibly activated in response to external stimuli examples include a mouse mammary tumor virus (MMTV) promoter, a tetracycline responsive promoter, a metallothionein promoter and a heat shock protein promoter.
  • MMTV mouse mammary tumor virus
  • a tetracycline responsive promoter examples include a tetracycline responsive promoter, a metallothionein promoter and a heat shock protein promoter.
  • the expression vector contains at least one selectable marker.
  • an auxotrophic marker LEU2, URA3, HIS3, TRP1, ura5, niaD
  • a drug resistance marker hygromycin, zeocin
  • G418r geneticin resistance gene
  • CUP1 copper resistance gene
  • fas2m, PDR4 Junji Inokoshi et al., Journal of Japanese Biochemical Society, vol. 64, p. 660, 1992 ; Hussain et al., Gene, vol. 101, p. 149, 1991 , respectively
  • a generally employed known method can be employed.
  • an electroporation method Mackenxie, D. A. et al., Appl. Environ. Microbiol., vol. 66, p. 4655-4661, 2000
  • a particle delivery method Japanese Unexamined Patent Application Publication No. 2005-287403
  • a spheroplast method Proc. Natl. Acad. Sci. USA, vol. 75, p. 1929, 1978
  • a lithium acetate method J. Bacteriology, vol. 153, p. 163, 1983
  • a method described in Methods in yeast genetics, 2000 Edition : A Cold Spring Harbor Laboratory Course Manual , or the like can be performed although the present invention is not limited thereto.
  • a non-human transformant obtained as described above can be cultured so as to allow the non-human transformant to produce a steviol glycoside.
  • a non-human transformant is preferably a yeast.
  • the non-human transformant is preferably cultured in a medium containing steviol.
  • the accumulated steviol glycoside can be extracted/purified to obtain the steviol glycoside of the present invention.
  • Extracts obtained from the leaves of four lines of novel stevia plants (Sample 1 (EM3-4), Sample 2 (EM2-27-8), Sample 3 (EM2-27-15) and Sample 4 (EM2-11)) developed at Suntory Global Innovation Center (SIC) were subjected to high performance liquid chromatography (HPLC)-mass spectrometry (MS) for the screening analysis of the contained steviol glycoside based on the molecular weights of a steviol glycoside that had a sugar chain formed of D-glucopyranosyl (glc), L-rhamnopyranosyl (rha) and xylopyranosyl (xyl).
  • HPLC high performance liquid chromatography
  • MS mass spectrometry
  • Sample 1 is a high-Reb.C plant having a genome polymorphism of A in the wild type being altered to T at the 60th nucleotide of the nucleotide sequence represented by SEQ ID NO:11 in the genome of a test plant.
  • a statistical analysis of the correlation between the phenotype having a high-RebC concentration and the polymorphism of SEQ ID NO:11 revealed that said polymorphism had a statistic correlation with the phenotype having a high-RebC concentration.
  • a process for preparing a test liquid was as follows: 10.0 mg each of lyophilized dried stevia leaves was weighed into a glass vial, to which 1.0 mL of water/methanol (1/1 vol/vol) was added as an extracting solvent, and then the resultant was subjected to ultrasonic irradiation in an ultrasonic cleaner (AS ONE, AS52GTU) at a set temperature of 25°C for 20 minutes, thereby obtaining a liquid extract of a steviol glycoside from the stevia leaves. The resultant was further 10-fold diluted with water/methanol and filtrated through a filter with a pore size of 0.45 ⁇ m (Nacalai tesque, Cosmonice filter S (solvent)) before being subjected to HPLC-MS.
  • AS ONE ultrasonic cleaner
  • triple quadrupole mass spectrometer LCMS-8030 (Shimadzu Corporation) equipped with an electrospray ionization (ESI) ion source was used.
  • the mass spectrometry measurement was carried out in a selected ion monitoring (SIM) mode by selecting the negative ion measurement mode and the m/z values.
  • SIM selected ion monitoring
  • the m/z values were selected by calculation based on the molecular weights of a steviol glycoside that had a sugar chain formed of D-glucopyranosyl (glc), L-rhamnopyranosyl (rha) and xylopyranosyl (xyl).
  • m/z 641.2 (glc (2)), 773.2 (glc (2), xyl (1)), 787.2 (glc (2), rha (1)), 803.2 (glc (3)), 935.3 (glc (3), xyl (1)), 949.3 (glc (3), rha (1)), 965.3 (glc (4)), 1095.4 (glc (3), rha (2)), 1097.4 (glc (4), xyl (1)), 1111.4 (glc (4), rha (1)), 1127.4 (glc (5)), 1257.5 (glc (4), rha (2)), 1259.5 (glc (5), xyl (1)), 1273.5 (glc (5), rha (1)), 1289.5 (glc (6)), 1435.6 (glc (6), rha (1)) were selected.
  • Peak areas (arbitrary unit) observed by STM measurement in HPLC-MS Compound name Rebaudioside A Rebaudioside C Rebaudioside D Rebaudioside M Compound represented by Formula (1) Rebaudioside N Retention time (min) 29.60 29.96 28.00 28.66 27.70 28.18 Peak area (Sample 1) 29,669,582 30,122,062 1,428,384 1,030,603 140,947 772,570 46.97% 47.69% 2.26% 1.63% 0.22% 1.22% Peak area (Sample 2) 23,762,676 24,201,473 2,253,735 1,029,837 97,388 1,211,504 45.21% 46.05% 4.29% 1.96% 0.19% 2.31 % Peak area (Sample 3) 15,386,726 5,872,656 3,585,775 3,296,579 89,988 896.549 52.82% 20.16% 12.31% 11.32% 0.31% 3.08% Peak area (Sample 4) 16,070,017 10,
  • the peak seen at the retention time (Rt) of 28.23 minutes matches the standard sample of rebaudioside N in terms of the mass value and the retention time. Meanwhile, no steviol glycoside has yet been reported to have a mass equivalent to that of rebaudioside N. Accordingly, the peak at Rt 27.73 minutes of the two peaks shown in Figure 2 was found to be an unknown substance. For Sample 4 whose rebaudioside C content was lower than the content of rebaudioside A and whose sugar chain elongation was shorter than other samples, the peak value at Rt 27.73 was lower than the detection limit.
  • a process for preparing test liquids were as follows: 10.0 mg each of lyophilized dried stevia leaves was weighed into a glass vial, to which 1.0 mL of water/methanol (1/1 vol/vol) was added as an extracting solvent, and then the resultant was subjected to ultrasonic irradiation in an ultrasonic cleaner (AS ONE, AS52GTU) at a set temperature of 25°C for 20 minutes, thereby obtaining the liquid extract of a steviol glycoside from the stevia leaves. The resultant was further 10-fold diluted with water/methanol and filtrated through a filter with a pore size of 0.45 ⁇ m (Nacalai tesque, Cosmonice filter S (solvent)) before being subjected to HPLC-MS.
  • AS ONE ultrasonic cleaner
  • HPLC-ESI-HRMS high performance liquid chromatography-electrospray ionization-accurate mass spectrometry
  • equipment for HPLC was configured by using Prominence LC-20AD (Shimadzu Corporation) as a liquid delivery unit LC pump and SM-C18 (4.6 x 250 mm) (from Imtakt) as a separation column.
  • the LC mobile phase was delivered using 0.2% acetic acid-containing Milli-Q water as mobile phase A and methanol as mobile phase B, where the binary gradient was such that the concentration of the mobile phase B was constantly maintained at 10% for 0-5 minutes, the concentration of the mobile phase B was shifted from 10% to 70% in the next 15 minutes, and further from 70% to 100% in the following 5 minutes.
  • the concentration of the mobile phase B was maintained at 100% for 5 minutes to end.
  • the flow rate of the mobile phase was 0.4 mL/min, and the stevia leaf liquid extract diluted and subsequently filtrated with a filter was injected for 5 ⁇ L.
  • Orbitrap Elite MS from Thermo Fisher Scientific
  • the mass spectrometry measurement was carried out in a negative ion measurement mode at m/z in a range of 150-2000 with resolution set to 60,000.
  • the MS/MS measurement was carried out by selecting the targeted m/z of 1273.5 and in a CID mode where fragmentation was induced by collision with an inert gas. Irradiation of energy required for fragmentation was performed at a standard collision energy unique to the apparatus, i.e. 35.
  • the MS/MS and MS 3 -fragmented mass spectra of rebaudioside N and the novel steviol glycoside are shown in Figure 3 .
  • rebaudioside N had the main peak at m/z of 803.37 corresponding to release of two glc moieties and one rha moiety.
  • the main peak was detected at m/z of 787.38 corresponding to release of three Glc moieties.
  • trisaccharide hemiacetal form (9) For synthesis of the trisaccharide hemiacetal form (9), a trisaccharide backbone was produced by condensation reaction between the appropriately protected glucose acceptor (5) and glucose donor (6), and the protecting group at the anomeric carbon of the reducing end was deprotected to give the trisaccharide hemiacetal form (9).
  • the resulting steviol glycoside (3) and trisaccharide hemiacetal form (9) were subjected to condensation via the Mitsunobu reaction, where a reaction with good and complete ⁇ -selectivity of 47% (only the ⁇ -form) proceeded.
  • the protecting groups of the resulting compound were deprotected, thereby obtaining the novel steviol glycoside (11).
  • rebaudioside C (1) (1.0 g, 1.05 mmol) purchased from Ark Pharm was dissolved in methanol (10 mL) and water (10 mL), added with 4 mol/L of sodium hydroxide (2.6 mL, 10.5 mmol) at room temperature, and refluxed at 100°C for 20 hours.
  • a novel steviol glycoside was generated from steviol in yeast.
  • a yeast capable of coexpressing four types of stevia-derived glycosylated enzyme genes UGT85C2, UGT91D2, UGT74G1 and UGT76G1 and Arabidopsis thaliana-derived UDP-rhamnose synthase gene AtRHM2 was bred.
  • the following primer sets were synthesized to perform PCR using cDNA prepared from stevia leaves as a template.
  • the PCR reaction solution (50 ⁇ l) had the following composition: 1 ⁇ l of stevia leaf-derived cDNA, 1 x KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 0.4 pmol/ ⁇ l of each primer, 1 mM MgSO 4 and 1U heat resistant KOD plus polymerase.
  • PCR reaction consisted of reaction at 95°C for 5 minutes, followed by amplification by a total of 30 cycles of reaction at 94°C for 0.5 minutes, 50°C for 0.5 minutes and 68°C for 2 minutes.
  • Each PCR product was subjected to electrophoresis with 0.8% agarose gel and ethidium bromide staining, by which an amplification band of nearly 1.4 kb in size was obtained as presumed from each template DNA.
  • PCR product was subcloned into pENTR-TOPO Directional vector (Invitrogen) according to a method recommended by the manufacturer.
  • DNA Sequencer model 3100 (Applied Biosystems) was used for sequencing by a primer walking process with a synthesized oligonucleotide primer, thereby confirming that all of the UGT genes of interest, namely, UGT85C2, UGT91D2, UGT74G1 and UGT76G1 were cloned.
  • templates and primers namely, template UGT85C2 and SrUGT85C2 set, template UGT91D2 and SrUGT91D2 set, template UGT74G1 and SrUGT74G1 set, template UGT76G1 and SrUGT76G1 set, and template AtAHM2 and AtAHM2 set, were used for PCR amplification using heat resistant KOD DNA polymerase (TOYOBO) and introduction of the restriction enzyme sites at both ends of each ORF.
  • TOYOBO heat resistant KOD DNA polymerase
  • the resulting DNA fragment was subcloned using Zero Blunt-TOPO PCR cloning kit (Invitrogen), and sequenced with DNA Sequencer model 3100 (Applied Biosystems) by a primer walking process with a synthesized oligonucleotide primer to confirm that each of the UGT genes of interest was cloned.
  • UGT85C2 was cleaved with restriction enzymes BglII and SalI, and linked to vector pESC-URA (Stratagene) that had been cleaved with restriction enzymes BamHI and SalI to give plasmid pESC-URA-UGT-5.
  • This plasmid pESC-URA-UGT-5 was cleaved with restriction enzymes NotI and PacI while UGT91D2 was also cleaved with restriction enzymes NotI and PacI. The resultants were linked to give pESC-URA-UGT56.
  • UGT76G1 was cleaved with restriction enzymes BamHI and SalI, and linked to vector pESC-HIS (Stratagene) that had been cleaved with the same restriction enzymes to give plasmid pESC-HIS-UGT-8.
  • This plasmid pESC-HIS-UGT-8 was cleaved with restriction enzymes NotI and PacI while UGT74G1 was also cleaved with NotI and PacI. The resultants were linked to give pESC-HIS-UGT78.
  • AtAHM2 was cleaved with restriction enzymes BamHI and XhoI while vector pESC-TRP (Stratagene) was cleaved with the same restriction enzymes. The resultants were linked to give plasmid pESC-TRP-AtAHM2.
  • Plasmids shown in Table 2 were introduced into Saccharomyces cerevisiae YPH499 strain (ura3-52 lys2-801 amber ade2-101 ochre trpl- ⁇ 63 his3- ⁇ 200 leu2- ⁇ 1 a) as a host by lithium acetate technique.
  • As transformed strains those that survived in a SC-Trp-Ura-His agar medium (6.7 g of yeast nitrogen base without amino acids, 20 g of glucose, 1.3 g of amino acid powder mix-Trp-Ura-His and 20 g of Bacto agar per 1L) were selected.
  • the amino acid powder mix-Trp-Ura-His was prepared by mixing adenine sulfate (2.5 g), L-arginine hydrochloride (1.2 g), L-aspartic acid (6.0 g), L-glutamic acid (6.0 g), L-leucine (3.6 g), L-lysine (1.8 g), L-methionine (1.2 g), L-phenylalanine (3.0 g), L-serine (22.5 g), L-threonine (12 g), L-tyrosine (1.8 g) and L-valine (9.0 g).
  • the resulting transformed strain was cultured as follows.
  • each transformed strain was seeded in 10 ml of a SC-Trp-Ura-His liquid medium (SC-Trp-Ura-His agar medium without Bacto agar) and shake cultured at 30°C for a day.
  • SC-Trp-Ura-His liquid medium SC-Trp-Ura-His agar medium without Bacto agar
  • 1 ml of the preliminary culture solution was seeded into 10 ml of SG-Trp-Ura-His liquid medium (6.7 g of yeast nitrogen base without amino acids, 20 g of galactose, and 1.3 g of amino acid powder mix-Trp-Ura-His per 1L) and shake cultured at 30°C for two days.
  • cDNA was synthesized using SuperScript II reverse transcriptase (Thermo Fischer Scientific) and random hexamer as a primer.
  • UGT74G1-r1 5'-CCCGTGTGATTTCTTCCACTTGTTC-3' (SEQ ID NO:30)
  • AtAHM2 AtAHM2-rl 5'-GCTTTGTCACCAGAATCACCATT-3' (SEQ ID NO:32)
  • GAL10p region (promoter region) PGAL10-f3 5'-GATTATTAAACTTCTTTGCGTCCATCCA-3' (SEQ ID NO:33)
  • GAL1p region promoter region
  • PGAL1-f3 5'-CCTCTATACTTTAACGTCAAGGAGAAAAAACC-3' (SEQ ID NO:34)
  • Culturing was performed under the same conditions as described above except that 0.5 ⁇ g or 2 ⁇ g of steviol (ChromaDex Inc.) was added to the liquid medium for the main culture per 1 ml of the medium. After culturing, the culture solution was separated into supernatant and cells by centrifugation. The culture supernatant was washed with acetonitrile, then subjected to a water-equilibrated Sep-Pak C18 column, washed with 20% acetonitrile, eluted with 80% acetonitrile, dried to solidify, and then dissolved in a small amount of 80% acetonitrile to prepare a glycoside sample. This glycoside sample was subjected to the following analysis.
  • samples were prepared by adding sucrose to pure water to give Brix of 0.5 to 3 in 0.5 increments.
  • Reb.A and the novel steviol glycoside were added to pure water at amounts indicated in Figure 8 to prepare beverage samples. All of the beverage samples were adjusted to have final Brix of 2 in terms of sucrose, provided that the sweetness levels were RebA: 300 and novel glycoside: 24.
  • the resulting beverage samples were subjected to sensory evaluation for rating attributes, namely, sweetness on-set, bitterness and lingering sweet aftertaste.
  • the novel steviol glycoside was found to have equal bitterness and shorter lingering sweet aftertaste as compared to the conventional sweetener Reb.A.
  • Three-level aqueous solutions with Brix of 5, 7 and 11 were used to evaluate the effect of the flavor controlling agent of the present invention to improve lingering aftertaste of Reb.A.
  • the added amounts of the flavor controlling agent made of the novel steviol glycoside of the present invention were 1, 3.5, 5 and 10 mass% in proportion based on the mass of added Reb.A.
  • a control sample (Cont) was added with Reb.A only and was not added with the flavor controlling agent of the present invention.
  • Three-level aqueous solutions with Brix of 5, 7 and 11 were used to evaluate the effect of the flavor controlling agent of the present invention to improve lingering aftertaste of Reb.D.
  • the added amounts of the flavor controlling agent made of the novel steviol glycoside of the present invention were 1, 3.5, 5 and 10 mass% in proportion based on the mass of added Reb.D.
  • a control sample (Cont) was added with Reb.D only and was not added with the flavor controlling agent of the present invention.
  • Two-level aqueous solutions with Brix of 5 and 7 were used to evaluate the effect of the flavor controlling agent of the present invention to enhance sweetness with respect to sugar (sucrose).
  • the added amounts of the flavor controlling agent made of the novel steviol glycoside of the present invention were 0.10, 0.44 and 0.80 mass% in proportion in terms of the amount of the sugar added for Brix of 5, and 0.10, 0.44 and 0.57 mass% in proportion for Brix of 7.
  • the vertical axes (sweetness intensity) of the graphs represent the rates of sweetness intensity actually sensed by the panelists with respect to the total sweetness level of the sugar and the flavor controlling agent (calculated provided that the sweetness level of the flavor controlling agent had a sweetness fold of 24). For all samples, a sweetness enhancement effect of about 2-7% was observed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Seasonings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP17888291.6A 2016-12-27 2017-12-26 Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant Pending EP3564251A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016253248 2016-12-27
PCT/JP2017/046806 WO2018124143A1 (fr) 2016-12-27 2017-12-26 Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant

Publications (2)

Publication Number Publication Date
EP3564251A1 true EP3564251A1 (fr) 2019-11-06
EP3564251A4 EP3564251A4 (fr) 2020-12-23

Family

ID=62710298

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17888291.6A Pending EP3564251A4 (fr) 2016-12-27 2017-12-26 Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant

Country Status (8)

Country Link
US (1) US20190352324A1 (fr)
EP (1) EP3564251A4 (fr)
JP (1) JP6970689B2 (fr)
CN (1) CN110167950B (fr)
AU (1) AU2017388706B2 (fr)
MY (1) MY204430A (fr)
NZ (1) NZ754394A (fr)
WO (1) WO2018124143A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075874A1 (fr) 2016-10-20 2018-04-26 The Coca-Cola Company Glycosides diterpéniques isolés à partir de stevia, compositions et procédés
EP3801041A4 (fr) * 2018-06-08 2022-05-25 PureCircle USA Inc. Glycosides de stéviol de haute pureté
US12302932B2 (en) 2019-08-09 2025-05-20 Suntory Holdings Limited Beverage having foam retentivity and method for improving foam retentivity of beverage

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020218382A1 (fr) * 2019-04-26 2020-10-29
AR119530A1 (es) * 2019-07-31 2021-12-22 Suntory Holdings Ltd Glucósido de esteviol, método para su producción y composición endulzante que contiene al mismo
CN110818750B (zh) * 2019-11-22 2020-11-06 江西师范大学 一种甜菊苷r的合成方法
CN112964812A (zh) * 2021-02-05 2021-06-15 山东省产品质量检验研究院 一种检测乳制品中8种甜味剂的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3436317B2 (ja) * 1993-11-24 2003-08-11 大日本インキ化学工業株式会社 ステビア甘味料の製造方法
JP4481702B2 (ja) 2004-03-31 2010-06-16 サントリーホールディングス株式会社 脂質生産菌の育種方法およびその利用
CN107033200A (zh) * 2008-10-03 2017-08-11 守田化学工业株式会社 新的甜菊醇糖苷
CN105671108A (zh) * 2010-06-02 2016-06-15 沃维公司 甜菊糖苷的重组生产
EP2970354B1 (fr) * 2013-03-15 2018-05-30 The Coca-Cola Company Glycosides de stéviol et leurs compositions
WO2016090460A1 (fr) 2014-12-08 2016-06-16 Qibin Wang Variété de plante à teneur élevée en rébaudioside c et compositions extraites de celle-ci ayant une teneur élevée en rébaudioside c et en glycosides de stéviol totaux
AU2017345605B2 (en) * 2016-10-20 2022-04-14 The Coca-Cola Company Diterpene glycosides isolated from Stevia, compositions and methods

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075874A1 (fr) 2016-10-20 2018-04-26 The Coca-Cola Company Glycosides diterpéniques isolés à partir de stevia, compositions et procédés
EP3528640A4 (fr) * 2016-10-20 2020-09-16 The Coca-Cola Company Glycosides diterpéniques isolés à partir de stevia, compositions et procédés
EP3801041A4 (fr) * 2018-06-08 2022-05-25 PureCircle USA Inc. Glycosides de stéviol de haute pureté
US12302932B2 (en) 2019-08-09 2025-05-20 Suntory Holdings Limited Beverage having foam retentivity and method for improving foam retentivity of beverage

Also Published As

Publication number Publication date
BR112019013208A2 (pt) 2019-12-10
JPWO2018124143A1 (ja) 2019-10-31
EP3564251A4 (fr) 2020-12-23
CN110167950A (zh) 2019-08-23
AU2017388706A1 (en) 2019-06-27
NZ754394A (en) 2023-04-28
AU2017388706B2 (en) 2022-04-21
CN110167950B (zh) 2023-03-10
MY204430A (en) 2024-08-28
WO2018124143A1 (fr) 2018-07-05
US20190352324A1 (en) 2019-11-21
JP6970689B2 (ja) 2021-11-24

Similar Documents

Publication Publication Date Title
EP3611179B1 (fr) Nouveau glycoside de stéviol et son procédé de production, et composition d'édulcorant contenant celui-ci
EP3564251A1 (fr) Nouveau glycoside de stéviol, son procédé de production et composition d'édulcorant le contenant
US20220256903A1 (en) Steviol glycosides
JP7002703B2 (ja) 新規ステビオール配糖体およびその製造方法、ならびにそれを含む甘味料組成物
CN114173555B (zh) 含有新型甜菊醇糖苷的植物体
BR112019013208B1 (pt) Composto, composição de adoçante, alimento ou bebida, método para produzir o composto, uso do composto, e, agente de controle do sabor
NZ785123B2 (en) Novel steviol glycoside, method for producing same, and sweetener composition containing same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201123

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20201117BHEP

Ipc: A23L 27/00 20160101ALI20201117BHEP

Ipc: A23L 2/60 20060101ALI20201117BHEP

Ipc: A23L 27/20 20160101ALI20201117BHEP

Ipc: C12P 19/44 20060101ALI20201117BHEP

Ipc: A01H 5/00 20180101ALI20201117BHEP

Ipc: C07H 1/00 20060101ALI20201117BHEP

Ipc: C12P 19/00 20060101ALI20201117BHEP

Ipc: C12P 21/02 20060101ALI20201117BHEP

Ipc: C07H 15/256 20060101AFI20201117BHEP

Ipc: C07K 14/415 20060101ALI20201117BHEP

Ipc: C12N 1/16 20060101ALI20201117BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230510